Skip to content
‹ Back to IndustriesHealthcare

The University of Kansas Announces Grant Funding for Knee Imaging Biomarkers Acquired from Weight Bearing CT

The University of Kansas Medical Center Research Institute Department of Rehabilitation Medicine has received a grant from the National Institute of Arthritis Musculoskeletal and Skin Diseases (NIAMS), one of the 27 Institutes and Centers at the National Institutes of Health (NIH), to fund three years of research on the usefulness of bilateral weight bearing CT…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

·
Share

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

The University of Kansas Medical Center Research Institute Department of Rehabilitation Medicine has received a grant from the National Institute of Arthritis Musculoskeletal and Skin Diseases (NIAMS), one of the 27 Institutes and Centers at the National Institutes of Health (NIH), to fund three years of research on the usefulness of bilateral weight bearing CT imaging and the critical need for more sensitive and affordable imaging biomarkers.

Osteoarthritis (OA) is the most prevalent form of arthritis, and the knee is the most commonly affected weight-bearing joint. The high cost of clinical trials creates a barrier for effective treatment development. Therefore, introduction of more specific and sensitive biomarkers could help to advance therapeutic development by reducing the time and sample sizes required for clinical trials.

Proposed Outcomes

There is an urgent need for imaging biomarkers that allow for identification of the best time in which patients will respond to treatment, and a means to analyze the efficiency of interventions. Early studies demonstrated the diagnostic value of bilateral weight-bearing CT in identifying knee OA symptoms accurately, as well as the feasibility to detect meniscal tears not detected by non-weight bearing MRI.

The grant from NIAMS will fund a study to validate the proposed imaging biomarkers and begin the qualification process for more responsive OA imaging biomarkers acquired using low-dose, bilateral standing CT imaging. Substantial advantages are offered over traditional radiographic biomarkers, including increased responsiveness to temporal changes in the joints, and a better reflection of the symptoms and severity of the disease. Additionally, this research will determine the prognostic validity of standing CT findings for detecting progression and worsening pain in people who currently suffer from or are at risk for knee OA.

Long-Term Impact

With the support of NIAMS, this research holds promise to detect joint damage earlier, and accelerate the pace of scientific discovery and clinical trials. The continuing impact will be evident through a shift in knee joint imaging with an improved biomarkers for monitoring knee OA disease features. If the additional meniscal extrusions detected on bilateral standing CT are clinically relevant, then standing CT could improve identification of the most appropriate patients for clinical trials – those at risk of rapid OA progression. Successful completion will provide improved biomarkers that will help those who suffer from knee OA through making clinical trials more affordable and accelerating therapeutic improvement.

For more information on visualizing cartilage and menisci in the knee using standing CT arthrogram versus MRI, click here.

Read more at curvebeam.com

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

Why young children die from local anesthetic overdoses in dental offices

Why young children die from local anesthetic overdoses in dental offices

Dentist anesthesiologists Stanley Malamed and Jason Brady told HealthFirst's Health First Talks podcast that fatal local anesthetic overdoses in young dental patients follow a chain of small errors: one-visit treatment plans, plain 3% mepivacaine, four quadrants injected at once and adult cartridges. Oral Health Group estimates LAST at 0.27 cases per 1,000 administrations. Brady caps his anesthetic tray at 90% of the maximum recommended dose.

  • 01Plain 3% mepivacaine is a sound one-quadrant drug for a child; beyond one quadrant, Malamed says epinephrine must be in the cartridge because it holds the drug in the nerve and keeps blood levels down.
  • 02Oral Health Group estimates LAST at about 0.27 cases per 1,000 local anesthetic administrations and reports cardiac signs come before any nervous system warning in about 20% of atypical cases.
  • 03Brady preps a tray holding 90% of the patient's calculated maximum recommended dose so a distracted operator cannot reach past it mid-case.

Oct 16, 2026

Suki raises $90M to take its AI scribe beyond note-taking

Suki raises $90M to take its AI scribe beyond note-taking

The funding backs a bet that scribes become clinicians' main AI interface, which changes how health systems evaluate them.

  • 01An ambient scribe already holds the patient context from the visit, and in early testing that context drove clinicians to prefer context-aware UpToDate answers 83% of the time.
  • 02Once a scribe starts answering clinical questions, note accuracy stops being enough to judge it. Regenstrief and Suki are building a framework that could add standardized metrics for answers too.

Oct 15, 2026

Harbor Health to buy 27 Village Medical clinics in Greater Houston

Harbor Health to buy 27 Village Medical clinics in Greater Houston

Harbor Health's purchase of Village Medical clinics in Houston is expected to close at the end of 2026. The 27 clinics are the primary care home for Harbor members in four counties.

  • 01Harbor's $0 specialist benefit only applies when a Harbor clinician makes the referral. For Houston employers, the test is whether employees will use the 27 clinics as their first stop.

Oct 8, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512